| Control conditions for randomised trials of behavioural interventions in psychiatry: a decision framework SM Gold, P Enck, H Hasselmann, T Friede, U Hegerl, DC Mohr, C Otte The Lancet Psychiatry 4 (9), 725-732, 2017 | 192 | 2017 |
| Stress and depression: a crucial role of the mineralocorticoid receptor ER De Kloet, C Otte, R Kumsta, L Kok, MHJ Hillegers, H Hasselmann, ... Journal of neuroendocrinology 28 (8), 2016 | 192 | 2016 |
| The Berlin Treatment Algorithm: recommendations for tailored innovative therapeutic strategies for multiple sclerosis-related fatigue C Veauthier, H Hasselmann, SM Gold, F Paul EPMA Journal 7, 1-16, 2016 | 87 | 2016 |
| Characterizing the phenotype of multiple sclerosis–associated depression in comparison with idiopathic major depression H Hasselmann, J Bellmann-Strobl, R Ricken, T Oberwahrenbrock, ... Multiple Sclerosis Journal 22 (11), 1476-1484, 2016 | 54 | 2016 |
| Pro-inflammatory monocyte phenotype and cell-specific steroid signaling alterations in unmedicated patients with major depressive disorder H Hasselmann, S Gamradt, A Taenzer, J Nowacki, R Zain, K Patas, ... Frontiers in Immunology 9, 2693, 2018 | 53 | 2018 |
| Ketamine as antidepressant? Current state and future perspectives H WW Hasselmann Current neuropharmacology 12 (1), 57-70, 2014 | 51 | 2014 |
| Short-term interval aerobic exercise training does not improve memory functioning in relapsing-remitting multiple sclerosis—a randomized controlled trial L Baquet, H Hasselmann, S Patra, JP Stellmann, E Vettorazzi, AK Engel, ... PeerJ 6, e6037, 2018 | 38 | 2018 |
| Scopolamine and depression: a role for muscarinic antagonism? H Hasselmann CNS & Neurological Disorders-Drug Targets (Formerly Current Drug Targets-CNS …, 2014 | 37 | 2014 |
| Reduced mitochondrial respiration in T cells of patients with major depressive disorder S Gamradt, H Hasselmann, A Taenzer, J Brasanac, V Stiglbauer, A Sattler, ... Iscience 24 (11), 2021 | 13 | 2021 |
| Short-term escitalopram treatment and hippocampal volume BR Godlewska, HWW Hasselmann, A Igoumenou, R Norbury, PJ Cowen Psychopharmacology 231, 4579-4581, 2014 | 12 | 2014 |
| Lancet Psychiatry SM Gold, P Enck, H Hasselmann | 4 | 2017 |
| The role of monocyte phenotype and steroid-related gene expression in major depressive disorder HWW Hasselmann | | 2020 |
| Short-term aerobic training does not improve memory functioning in relapsing remitting multiple sclerosis–a randomized controlled trial L Baquet, H Hasselmann, S Patra, JP Stellmann, E Vettorazzi, AK Engel, ... bioRxiv, 366161, 2018 | | 2018 |
| Bicycle ergometry does not improve verbal memory in mild relapsing remitting MS-results of a RCT L Baquet, H Hasselmann, S Patra, J Poettgen, JP Stellmann, A Engel, ... MULTIPLE SCLEROSIS JOURNAL 23, 950-951, 2017 | | 2017 |
| Cell-specific immune regulation and metabolic dysfunction in major depressive disorder H Hasselmann, A Taenzer, S Gamradt, K Patas, D Piber, C Otte, SM Gold European Neuropsychopharmacology 27, S782-S783, 2017 | | 2017 |
| Pharmakotherapie bei Multipler Sklerose F Paul Zeitschrift für Komplementärmedizin 9 (05), 42-46, 2017 | | 2017 |
| Antidepressant and Abuse Potential of Ketamine HWW Hasselmann Neuropathology of Drug Addictions and Substance Misuse, 639-648, 2016 | | 2016 |
| Characterizing the phenotype of depression in multiple sclerosis: relative contribution of somatic symptoms as a moderator of depression severity H Hasselmann, J Bellmann-Strobl, R Ricken, T Oberwahrenbrock, C Otte, ... MULTIPLE SCLEROSIS JOURNAL 21, 114-115, 2015 | | 2015 |
| Interaction of Ketamine and Cannabis in Bipolar Disorder H Hasselmann Biological Psychiatry, 2015 | | 2015 |
Friedemann PaulProfessor für klinische Neuroimmunologie, Charité Universitätsmedizin BerlinBestätigte E-Mail-Adresse bei charite.de
